Panelists reviewed the latest advancements in clinical testing for melanoma, targeted therapy implications, and strategies for patient selection at a session on genetic and molecular testing at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
A panel discussion at the 2022 American Academy of Dermatology Annual Meeting addressed the association between food and skin manifestations, as well as dietary triggers and recommendations in the management of a myriad of dermatologic conditions.
The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a new exploratory study.
Soumya Chakravarty, MD, PhD, FACP, FACR, strategic lead, Rheumatology Therapeutic Area at Janssen, speaks on nontherapeutic approaches to manage symptom burden of psoriatic arthritis.
Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.
Jonathan Silverberg, MD, PhD, MPH, discusses key differences regarding epidemiology, genetic risk factors, and clinical manifestations of pediatric and adult-onset atopic dermatitis, as well as recommended therapeutic approaches for adult patients.
The lack of racial representation in dermatology education prompted the launch of Project IMPACT, explained Art Papier, MD, dermatologist, CEO, VisualDx at the 2022 American Academy of Dermatology Annual Meeting.
An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal congestion severity, whereas benralizumab was least effective.
The FDA accepts an application for a drug to treat amyotriphic lateral sclerosis (ALS) for review; vaccines have been found to reduce people’s risk for developing long COVID-19; COTA announces Miruna Sasu, PhD, as its new president and CEO.
There is evidence that people with HIV may have increased risk of cardiovascular disease and researchers are still trying to understand why, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School.
Angela Storseth-Cooper, associate director, Government Relations & Public Policy, The US Oncology Network, discusses state-level legislation that community oncology practices can leverage to address issues involving pharmacy benefit managers and the vertical integration of health plans and specialty pharmacies.
Lower risk of discontinuation was found with ustekinumab vs the biologics adalimumab, secukinumab, and ixekizumab, in the treatment of patients with moderate to severe psoriasis.
The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty pharmaceutical pipeline, with a featured preconference session on bias in health care.
The World Health Organization warns of long-term health impacts from the Ukraine crisis; states sign legislation aimed at curbing abortion access; over 14 million Americans signed up for health insurance through the Affordable Care Act.
This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.
Coverage of COVID-19 tests and treatment bills halted for uninsured; Moderna low-dose vaccine in children under 6 years of age shows promise in early clinical trial findings; Pfizer recalls blood pressure medications due to potential carcinogen.
Patients with chronic rhinosinusitis (CRS) with nasal polyps exhibited significant improvement in olfactory function when treated with a combination of oral and nasal steroids vs nasal steroids alone.
A study found that dementia was associated with patient mortality and length of stay when patients with chronic obstructive pulmonary disease (COPD) were admitted to a hospital.
This new study from Germany evaluated the use of and satisfaction with continuous glucose monitors (CGMs) since health insurance companies in the country began reimbursement of the technology in 2016 for persons with insulin-dependent diabetes.
At the 2022 Community Oncology Conference, Elizabeth Spurlock, MA, PHR, director, Human Resources Business Partner, Texas Oncology, discussed the prevalence of burnout among physicians, staff, and administrators, and several strategies to reduce risk and support the health care workforce.
Chronic kidney disease (CKD) and diabetes were associated with a higher risk of neurocognitive decline, but kidney disease stage did not appear to affect risk.
The special enrollment period for Affordable Care Act (ACA) coverage has opened to low-income Americans; the FDA approves the first drug for a rare genetic epilepsy disorder; the National Institutes of Health to launch biomarker testing program for pediatric tumors.
On this episode of Managed Care Cast, Teresa Tyson, DNP, MSN, FNP-BC, FAANP, and Paula Hill-Collins, DNP, MSN, FAANP, discuss how The Health Wagon, a free mobile-based and nurse-managed clinic, provides accessible health care to rural residents in Virginia's Appalachian region.
The Global and Professional Direct Contracting model is going to be replaced with a new accountable care organization (ACO) model, which addresses some of the pushback there had been on the direct contracting model, said Michael Chernew, PhD.
